Novel therapeutic compounds for prostate adenocarcinoma treatment: An analysis using bioinformatic approaches and the CMap database.
Adult
Collagen Type I, alpha 1 Chain
Computational Biology
/ methods
Databases, Genetic
Drug Compounding
/ methods
Gabexate
/ therapeutic use
Gene Expression Profiling
/ methods
Humans
Kaplan-Meier Estimate
Male
Piperazines
/ therapeutic use
Prostate
/ pathology
Prostatic Neoplasms
/ drug therapy
Tolnaftate
/ therapeutic use
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
18 Dec 2020
18 Dec 2020
Historique:
received:
16
05
2020
accepted:
17
11
2020
entrez:
29
12
2020
pubmed:
30
12
2020
medline:
13
1
2021
Statut:
ppublish
Résumé
Prostate adenocarcinoma is the most frequently diagnosed malignancy, particularly for people >70 years old. The main challenge in the treatment of advanced neoplasm is bone metastasis and therapeutic resistance for known oncology drugs. Novel treatment methods to prolong the survival time and improve the life quality of these specific patients are required. The present study attempted to screen potential therapeutic compounds for the tumor through bioinformatics approaches, in order to provide conceptual treatment for this malignant disease. Differentially expressed genes were obtained from the Gene Expression Omnibus database and submitted into the Connectivity Map database for the detection of potentially associated compounds. Target genes were extracted from the search results. Functional annotation and pathway enrichment were performed for the confirmation. Survival analysis was used to measure potential therapeutic effects. It was revealed that 3 compounds (vanoxerine, tolnaftate, and gabexate) may help to prolong the disease-free survival time from tumor metastasis of patients with the tumor. A total of 6 genes [also-keto reductase family 1 member C3 (AKR1C3), collagen type III α 1 chain (COL3A1), lipoprotein lipase (LPL), glucuronidase, β pseudogene 11 (GUSBP11), apolipoprotein E (APOE), and collagen type I α 1 chain (COL1A1)] were identified to be the potential therapeutic targets for the aforementioned compounds. In the present study, it was speculated that 3 compounds may function as the potential therapeutic drugs of bone metastatic prostate adenocarcinoma; however, further studies verifying vitro and in vivo are necessary.
Identifiants
pubmed: 33371142
doi: 10.1097/MD.0000000000023768
pii: 00005792-202012180-00090
pmc: PMC7748316
doi:
Substances chimiques
COL1A1 protein, human
0
Collagen Type I, alpha 1 Chain
0
Piperazines
0
Tolnaftate
06KB629TKV
Gabexate
4V7M9137X9
vanoxerine
90X28IKH43
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23768Subventions
Organisme : Innovation Project of Guangxi Graduate Education
ID : YCSW2018099
Informations de copyright
Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
Références
Lancet Oncol. 2015 May;16(5):509-21
pubmed: 25888263
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Med Oncol. 2015 Apr;32(4):112
pubmed: 25761858
Urol Oncol. 2018 Jun;36(6):272-282
pubmed: 29650324
Surg Today. 2000;30(7):614-21
pubmed: 10930227
J Bone Oncol. 2017 Sep 11;9:1-9
pubmed: 28948139
Biochem Res Int. 2012;2012:398697
pubmed: 22028972
Cancer Lett. 2009 Apr 8;276(1):14-20
pubmed: 19091461
Int J Clin Exp Pathol. 2015 Feb 01;8(2):1985-90
pubmed: 25973093
Cancer Res. 2006 Mar 1;66(5):2815-25
pubmed: 16510604
J Ovarian Res. 2016 Mar 31;9:20
pubmed: 27036110
Biochem Pharmacol. 2004 Dec 15;68(12):2359-66
pubmed: 15548382
Lancet. 2016 Jan 2;387(10013):70-82
pubmed: 26074382
PLoS One. 2012;7(7):e41347
pubmed: 22911782
Oncogene. 2006 May 25;25(22):3170-85
pubmed: 16607286
Gene. 2019 Jan 10;681:15-25
pubmed: 30266498
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Lancet Oncol. 2015 Feb;16(2):152-60
pubmed: 25601341
Pancreas. 2004 Aug;29(2):123-31
pubmed: 15257104
Mol Cell Proteomics. 2002 Apr;1(4):304-13
pubmed: 12096112
BMC Med Genomics. 2016 Jul 30;9(1):51
pubmed: 27475327
Nucleic Acids Res. 2019 Jan 8;47(D1):D590-D595
pubmed: 30321428
Prostate. 2013 Feb 15;73(3):242-9
pubmed: 22821767
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Am J Pathol. 2005 Apr;166(4):1173-86
pubmed: 15793297
BJU Int. 2008 Jan;101(1):5-10
pubmed: 17760888
Cancer Lett. 2011 Jul 1;306(1):52-9
pubmed: 21444150
Clin Cancer Res. 2017 Jan 1;23(1):3-5
pubmed: 27903676
Mod Pathol. 2010 Apr;23(4):539-46
pubmed: 20118910
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
N Engl J Med. 2006 Mar 9;354(10):1021-30
pubmed: 16525139
Nucleic Acids Res. 2019 Jan 8;47(D1):D955-D962
pubmed: 30407550
Addict Biol. 2007 Jun;12(2):133-51
pubmed: 17508985
Breast Cancer Res Treat. 2014 Aug;147(1):185-91
pubmed: 25048467
Science. 1988 Apr 29;240(4852):622-30
pubmed: 3283935
Clin Cancer Res. 2018 Nov 1;24(21):5433-5444
pubmed: 30042207
Cancer Res. 2008 Jun 1;68(11):4447-54
pubmed: 18519708
Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):E172-81
pubmed: 26621741
Oncotarget. 2016 May 31;7(22):32592-606
pubmed: 27081040
Cell. 2017 Nov 30;171(6):1437-1452.e17
pubmed: 29195078
Chaos. 2011 Jun;21(2):023121
pubmed: 21721763
Cancer Chemother Pharmacol. 2011 Oct;68(4):889-96
pubmed: 21290244
Antimicrob Agents Chemother. 1986 May;29(5):858-60
pubmed: 3524433
Neoplasia. 2007 Oct;9(10):830-9
pubmed: 17971903
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
J Biol Regul Homeost Agents. 2017 Oct-Dec;31(4):1067-1072
pubmed: 29254316
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
Curr Med Chem. 2009;16(1):66-93
pubmed: 19149563
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
Clin Cancer Res. 2008 Sep 1;14(17):5519-30
pubmed: 18765544
J Pathol. 2008 Feb;214(3):357-67
pubmed: 18044827
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Mol Cell Biol. 2005 Oct;25(19):8581-91
pubmed: 16166639
J Cardiovasc Electrophysiol. 2010 Mar;21(3):301-10
pubmed: 19817928
JOP. 2007 Jul 09;8(4 Suppl):501-8
pubmed: 17625307
Discov Med. 2018 May;25(139):211-223
pubmed: 29906404
Int J Cancer. 2009 Feb 1;124(3):734-8
pubmed: 19004026
J Biol Chem. 1988 May 5;263(13):6226-32
pubmed: 2834369
Oncogene. 2017 Apr 6;36(14):1925-1938
pubmed: 27694892
Oral Oncol. 2017 Feb;65:94-101
pubmed: 28109476
J Health Econ. 2003 Mar;22(2):151-85
pubmed: 12606142
J Clin Oncol. 2000 Mar;18(5):1135-49
pubmed: 10694567
J Clin Invest. 2006 Jun;116(6):1561-70
pubmed: 16741576
Cancer Discov. 2018 Mar;8(3):304-319
pubmed: 29196464
Biochim Biophys Acta Proteins Proteom. 2017 Sep;1865(9):1114-1122
pubmed: 28627476
Aust Prescr. 2018 Oct;41(5):154-159
pubmed: 30410212
Eur Urol. 2012 Jun;61(6):1079-92
pubmed: 22424666
Clin Cancer Res. 2017 Jan 1;23(1):73-80
pubmed: 27635088
J Vet Pharmacol Ther. 2003 Feb;26(1):5-29
pubmed: 12603774
Int J Cancer. 2008 Oct 1;123(7):1693-8
pubmed: 18646186
Br J Cancer. 2012 Apr 24;106(9):1564-70
pubmed: 22454078
Nat Rev Cancer. 2002 May;2(5):389-96
pubmed: 12044015
Mol Cancer Res. 2008 Aug;6(8):1259-67
pubmed: 18708358
Clin Cancer Res. 2018 Feb 15;24(4):927-938
pubmed: 29158269
Cancer Lett. 2015 Feb 28;357(2):448-53
pubmed: 25511741
J Pharmacol Exp Ther. 2003 Apr;305(1):298-305
pubmed: 12649382
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
World J Gastroenterol. 2015 Oct 7;21(37):10493-501
pubmed: 26457010
Tumori. 2013 Jul-Aug;99(4):523-9
pubmed: 24326842
Curr Opin Lipidol. 2016 Jun;27(3):233-41
pubmed: 27031275
Cancer Metastasis Rev. 2014 Sep;33(2-3):413-27
pubmed: 24384911
Biochem Biophys Res Commun. 2016 Sep 16;478(2):845-51
pubmed: 27507215
Proc Natl Acad Sci U S A. 1994 May 24;91(11):5022-6
pubmed: 8197176
Physiol Res. 2000;49 Suppl 1:S63-9
pubmed: 10984073
J Biol Chem. 1985 Feb 25;260(4):2315-20
pubmed: 2857713
J Cell Physiol. 2018 Jun;233(6):4895-4906
pubmed: 29194609